1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6818E8DBC49D0B5AC6525830500242286
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-digital-patient-engagement-strategies-global-emerging-developed-markets-staffing-investment-vendor-utilization?opendocument
18
19opendocument
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Digital Patient Engagement

Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Staffing, Investment and Vendor Utilization for Digital Engagement

ID: 5523


Features:

8 Info Graphics

23 Data Graphics

390+ Metrics


Pages/Slides: 42


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Staffing, Investment and Vendor Utilization for Digital Engagement”

STUDY OVERVIEW

One of the key factors that plays an important role in the effectiveness of digital patient engagement programs is resource allocation. As a result, pharmaceutical, biotechnology and medical device organizations need to optimize the staffing and spend levels of their Digital Patient Engagement groups to maximize efficiency and impact.

Best Practices, LLC undertook this research to identify current staffing and spending levels for digital patient engagement programs. The study also examines vendor utilization and legal/compliance involvement for digital patient engagement. Specifically, this study delivers digital patient engagement benchmarks around staffing allocation; outsourcing levels; spending; and involvement level of legal and compliance department.

Insights in this benchmarking study are presented into three segments: Global Market Segment, Developed Market Segment and Emerging Market Segment.

KEY TOPICS


  • Staffing allocation and outsourcing
  • Spending on patient marketing programs and activities
  • Involvement level of legal and compliance department
  • Top vendor insights
  • Investment trends

KEY METRICS


  • Please indicate the influence of listed factors on staffing levels of Digital Patient Engagement groups
  • How many FTEs are allocated to Digital Patient Engagement for your area of responsibility?
  • What percentage of external engagement budget for patient engagement and HCP outreach is devoted to digital initiatives in your therapeutic area(s)?
  • Which of the listed group(s) invest resources or budget for Digital Patient Engagement activities?
  • Which of the listed activities and programs are included in the total current Digital Patient Engagement spend in your therapeutic area(s)?
  • What is the level of the legal and compliance departments’ involvement in the listed Patient Engagement activities?
  • Please rate the importance of listed patient advocacy group activities and support services when building and maintaining Digital Patient Engagement programs
  • How much of your Digital Patient Engagement budget is spent on each phase?

SAMPLE KEY FINDINGS


  • Emerging markets spend a smaller portion of their patient engagement budget (15%) on digital activities compared to Global (33%) and Developed markets (41%).

METHODOLOGY


Best Practices, LLC engaged 54 industry professionals involved in digital patient engagement programs at 34 leading pharmaceutical, biotechnology and medical device companies through a benchmarking survey.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Research; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Allergan; Astellas; AstraZeneca; Bayer; B. Braun; Cadila Pharmaceuticals; Cordis; Ferring Pharmaceuticals; Fidia; Genentech; Horizon Pharma; Incyte; Ipsen; Janssen; LEO Pharma; Medtronic; Meyer; MSD; Novartis; Novo Nordisk; Parexel; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Roche; Sanofi; Sunovion; Synexus; Teva Pharmaceutical Industries Ltd; UCB Pharma; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.